MEMORANDUM

To: Collaborative Pharmaceutical Task Force

Philip P. Burgess, MBA, DPh, RPh, Chairperson
Deborah Hagan, Secretary, Department of Financial & Professional Regulation
Scott Meyers, MS, RPh
Helga Brake, PharmD
Brian H. Kramer, RPh, MBA
Jerry L. Bauman, PharmD
Adam Bursua, PharmD
Scott A. Reimers
Lemrey Al Carter, RPh
Garth Reynolds, RPh
Thomas Stiede

From: Lucienne Doler, Assistant General Counsel

Date: June 28, 2019

Re: Meeting – July 9, 2019

The Collaborative Pharmaceutical Task Force will convene a meeting at 1:30 P.M. CST on Tuesday, July 9, 2019, in the Chicago office of the Department of Financial and Professional Regulation, 100 West Randolph Street, Chicago, Illinois 60601 – 2nd Floor, Room 2-025, and via video conference at the Springfield office of the Department of Financial and Professional Regulation, 320 West Washington Street, Springfield, IL 62786 – 3rd Floor, Room 376. Please notify me at your earliest convenience if you are not able to attend the meeting.

This meeting will be accessible to handicapped individuals in compliance with Executive Order #5 and pertinent state laws upon notification of anticipated attendance. Handicapped persons planning to attend and needing special accommodations should contact me either by telephone or letter, at least five days prior to the meeting date.
COLLABORATIVE PHARMACEUTICAL TASK FORCE AGENDA
July 9, 2019
1:30 P.M.

I. Roll Call & Introductions

II. Old Business
   A. Approval of Minutes

III. New Business
   A. Review of Progress Chart reflecting previous votes and agenda items that still need to be addressed as required by the legislation. - Phil Burgess
   B. Final vote on specific amendments to the language in the “Proposed Changes Related to Duties of Pharmacy Technicians.” - Scott Meyers, Garth Reynolds, Brian Kramer and Jerry Bauman
   C. Discussion and potential vote on language regarding requiring “pharmacy prescription systems to contain mechanisms to require prescription discontinuation orders to be forwarded to a pharmacy” (as specified in 225 ILCS 85/4.5). - Adam Bursa
   D. Discussion and potential vote regarding whether any enhancements are needed to the “reporting requirements” for “pharmacy employee terminations,” considering the reporting requirements contained in 225 ILCS 85/30.1. - Phil Burgess
   E. Discussion regarding the appropriate recommendations to address the standard containing the phrase “to require patient verification features for pharmacy automated prescription refills,” contained in 225 ILCS 85/4.5(2). - Phil Burgess
   F. Discussion regarding the appropriate recommendation to address the standard containing the phrase “to require that automated prescription refills notices clearly communicate to patients the medication name, dosage strength, and any other information required by the Department governing the use of automated dispensing and storage systems to ensure that discontinued medications are not dispensed to a patient by a pharmacist or by any automatic refill dispensing systems,” contained in 225 ILCS 85/4.5(2). - Phil Burgess
   G. Discussion and possible votes regarding draft language explaining the rational for the Collaborative Pharmaceutical Task Force’s approved recommendations voted on at previous meetings. - Garth Reynolds and Scott Meyers
   H. General Discussion

IV. Adjournment